Location History:
- Munich, DE (2010 - 2012)
- Bayreuth, DE (2011 - 2023)
Company Filing History:
17 out of 25 
4 out of 48 
4 out of 10 
Years Active: 2010-2025
Title: Thomas Scheibel: Innovator in Antigen Delivery Systems
Introduction
Thomas Scheibel, an accomplished inventor based in Bayreuth, Germany, has made significant contributions to the field of biotechnology. With a portfolio of 18 patents, Scheibel focuses on developing innovative solutions that enhance antigen delivery systems, aiming to improve therapeutic treatments and immune responses.
Latest Patents
One of Thomas Scheibel's latest patents is centered around "Articles comprising a silk polypeptide for antigen delivery." This invention involves a polypeptide that integrates a silk polypeptide and an antigen. The article derived from this polypeptide is designed for pharmaceutical applications, targeting the induction of immune responses and serving both prophylactic and therapeutic purposes for various diseases. This groundbreaking work exemplifies his commitment to advancing medical treatments through innovative technology.
Career Highlights
Throughout his career, Thomas Scheibel has worked with prominent organizations, including Amsilk GmbH and Ludwig Maximilians University Munich. At Amsilk, he has contributed his expertise in the development and commercialization of silk-based biomaterials. His role at Ludwig Maximilians University Munich has also allowed him to engage in cutting-edge research, further solidifying his position as a leader in his field.
Collaborations
In his journey as an inventor, Thomas Scheibel has collaborated with talented individuals such as Daniel Huemmerich and Lin Romer. These partnerships have fostered creativity and innovation, enabling the development of advanced technologies in antigen delivery systems.
Conclusion
Thomas Scheibel's contributions to the field of biotechnology, particularly in antigen delivery systems, highlight his innovative spirit and commitment to improving healthcare solutions. With his notable patents and collaborative efforts, he continues to pave the way for future advancements in medical therapies.